Werewolf transforms into Ambros via reverse merger to support phase 3 push for rare disease drug

Werewolf Therapeutics’ hunt for strategic alternatives has ended. Ambros Therapeutics has agreed to merge with Werewolf in an all-stock deal and has raised $150 million, positioning the biotech to take its lead rare disease drug candidate through to a filing for approval.